跳至主要内容
临床试验/PER-045-04
PER-045-04已完成未知

CLINICAL STUDY PHASE III RANDOMIZED, MULTICENTER, DOUBLE-BLIND, CONTROLLED WITH PLACEBO, OF 2 ARMS OF GW572016 ORAL IN COMBINATION WITH PACLITAXEL IN PATIENTS NOT TREATED PREVIOUSLY FOR ADVANCED OR METASTATIC BREAST CANCER

GLAXOSMITHKLINE PERU S.A.,0 个研究点目标入组 40 人开始时间: 2004年7月14日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 0(—)

入选标准

  • Signed Informed Consent
  • Able to swallow an oral medication
  • Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram
  • Adequate kidney and liver function
  • Adequate bone marrow function
  • Tumor tissue available for testing
  • Prior adjuvant or neoadjuvant therapy is permitted with an anthracycline or anthracenedione-containing regimen however, subjects must have had cumulative doses of less than 360 mg/m2 of doxorubicin, 720 mg/m2 of epirubicin, or 72 mg/m2 of mitoxantrone
  • No Her2/neu overexpression in tumor tissue tested or status unknown if tissue has never been tested

排除标准

  • Prior treatment regimens for advanced or metastatic breast cancer.
  • Pregnant or lactating
  • Conditions that would effect the absorption of an oral drug
  • Active infection
  • Brain metastases
  • Treatment with EGFR (Endothelial Growth Factor Receptor) inhibitor.
  • Known hypersensitivity to Taxol or excipients of Taxol
  • Peripheral neuropathy of Grade 2 or greater is not permitted
  • Severe Cardiovascular disease or cardiac disease requiring a device.
  • Serious medical or psychiatric disorder that would interfere with the patient´s safety or informed consent.

研究者

发起方
GLAXOSMITHKLINE PERU S.A.,

相似试验

进行中(未招募)
不适用
The purpose of the study is to compare and evaluate the generic Brinzolamide ophthalmic suspension with a registered and marketed Brinzolamide ophthalmic suspension as a treatment for ocular hypertension and glaucomaPatients suffering from open angle glaucoma and ocular hypertension with an elevated IOP, higher than 22mmHg and and lower or equal than 35 mmHg
EUCTR2011-003692-12-PLAZAD Pharma AG90
已完成
不适用
A phase III multicentre, randomised, controlled, clinical trial to assess the safety and efficacy of injectable paromomycin in patients with visceral leishmaniasis (India)Visceral leishmaniasis (VL)Infections and Infestations
ISRCTN68386084ICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)667
进行中(未招募)
1 期
RANDOMIZED PHASE III MULTICENTRE STUDY INVESTIGATING THE ROLE OF LETROZOLE IN HEAVILY PRETREATED RECURRENT OVARIAN CANCERADVANCED OVARIAN CANCERMedDRA version: 21.1Level: PTClassification code 10054913Term: Serous cystadenocarcinoma ovarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-001623-12-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE236
已完成
不适用
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
PER-055-04BRISTOL MYERS SQUIBB COMPANY,
已完成
1 期
MULTICENTRIC STUDY, IN PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED WITH PLACEBO, TO EVALUATE THE SAFETY AND EFFICACY OF BMS-298585 IN COMBINATION WITH METFORMIN, FOR THE TREATMENT OF INDIVIDUALS WITH DIABETES TYPE 2 THAT PRESENT AN INAPPROPRIATE CONTROL WITH METFORMIN AS MONOTHERAPY.
PER-041-03BRISTOL MYERS SQUIBB COMPANY,